Auxergen Recognized as Company to Watch by Baltimore Business Journal

Baltimore, Maryland – January 24, 2025

Auxergen has been named one of the top eight “Companies to Watch” in Baltimore for 2025
by the Baltimore Business Journal, a publication reaching over 2.3 million readers annually.

This recognition coincides with the fifth anniversary of Auxergen’s incorporation at the
Institute of Marine and Environmental Technology (IMET) on April 11, 2020. In support of its
expanding research capabilities, Auxergen has recently expanded its laboratory facilities at
IMET, equipped with advanced technology and capacity for 14 researchers.

Further achievements include the attainment of Qualified Maryland Biotechnology
Company (QMBC) status for 2025 and participation in representing Maryland and United
States biotechnology interests in Washington D.C.

Auxergen has developed nine novel biologic solutions aimed at addressing human and
agricultural challenges. The company has published 14 peer-reviewed scientific papers
and has facilitated the training of numerous students, many of whom have pursued
advanced studies at institutions such as Harvard University, Cornell University, and Johns
Hopkins University.

“We are building on the momentum established over the past five years to advance our
biotechnological innovations,” stated Gregory Contreras, CEO and Founder of Auxergen.
“This recognition underscores our commitment to impactful research and development in
the biotech sector.”

About Auxergen Inc.

Auxergen Inc. was Founded in 2020 at the Institute of Marine and Environmental
Technology (IMET), it now has presence in the E.U. Auxergen is a leader in bacteriophages
and biologic solutions to human and agricultural diseases. Committed to advancing public
health, Auxergen leverages cutting-edge research to address emerging viral threats.

Media Inquiries:

443.929.9757

info@auxergen.com